Cargando…

Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays

AIM: To compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with (125)I-recombinant hirudin. METHODS: 2.0 mg/kg (125)I-recombinant hirudin were injected intravenously into rats. The recombinant hirudins in the plasma w...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Su-yun, Jiao, Jian, Zhang, Ting-ting, Xu, Yong-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681893/
https://www.ncbi.nlm.nih.gov/pubmed/23785400
http://dx.doi.org/10.1371/journal.pone.0064336
_version_ 1782273331929546752
author Jiang, Su-yun
Jiao, Jian
Zhang, Ting-ting
Xu, Yong-ping
author_facet Jiang, Su-yun
Jiao, Jian
Zhang, Ting-ting
Xu, Yong-ping
author_sort Jiang, Su-yun
collection PubMed
description AIM: To compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with (125)I-recombinant hirudin. METHODS: 2.0 mg/kg (125)I-recombinant hirudin were injected intravenously into rats. The recombinant hirudins in the plasma was analyzed by chromogenic substrate assay, enzyme-linked immunosorbent assay (ELISA), total radioisotope assay (RA) and trichloroacetic acid pre-treated total radioisotope assay (TCA-RA). RESULTS: The chromogenic substrate assay standard curve was linear over the concentration range from 3.12 to 40.00 ng/ml for the recombinant hirudin in plasma. The relative standard deviations (RSD) for the intra- and inter-day variation were 5.0 to 6.3% and 11.9 to 12.6%, respectively. The recoveries of recombinant hirudin was 89.8% to 100.7%. The limit of quantification (LOQ) was 3.12 ng/ml. The concentration-time curve of the recombinant hirudin in the plasma could be explained as a two-compartment model. Pharmacokinetic parameters, including the half-life of distribution phase (t(1/2) α), the half-life of elimination phase (t(1/2) β), volume of apparent distribution (Vd), and area under the concentration-time curve from zero to infinite time (AUC(0–t)) were 7.59 min, 46.99 min, 0.17 L/kg, and 204.5 mg/L/min, respectively, as determined by chromogenic substrate assay; 6.41 min, 47.28 min, 1.24 L/kg, and 575.18 mg/L/min, respectively, as determined by ELISA; 3.69 min, 701.90 min, 0.04 L/kg, and 4189 mg/L/min, respectively as determined by RA; and 4.57 min, 724.9 min, 0.09 L/kg, and 2329 mg/L/min, respectively, as determined by TCA-RA. CONCLUSIONS: The chromogenic substrate assay on the concentration dynamics of the recombinant hirudin in the plasma is a specific, sensitive, and accurate analytical method for pharmacokinetic studies. Moreover, the pharmacokinetic parameters determined by the chromogenic substrate assay and ELISA are congruent except for AUC.
format Online
Article
Text
id pubmed-3681893
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36818932013-06-19 Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays Jiang, Su-yun Jiao, Jian Zhang, Ting-ting Xu, Yong-ping PLoS One Research Article AIM: To compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with (125)I-recombinant hirudin. METHODS: 2.0 mg/kg (125)I-recombinant hirudin were injected intravenously into rats. The recombinant hirudins in the plasma was analyzed by chromogenic substrate assay, enzyme-linked immunosorbent assay (ELISA), total radioisotope assay (RA) and trichloroacetic acid pre-treated total radioisotope assay (TCA-RA). RESULTS: The chromogenic substrate assay standard curve was linear over the concentration range from 3.12 to 40.00 ng/ml for the recombinant hirudin in plasma. The relative standard deviations (RSD) for the intra- and inter-day variation were 5.0 to 6.3% and 11.9 to 12.6%, respectively. The recoveries of recombinant hirudin was 89.8% to 100.7%. The limit of quantification (LOQ) was 3.12 ng/ml. The concentration-time curve of the recombinant hirudin in the plasma could be explained as a two-compartment model. Pharmacokinetic parameters, including the half-life of distribution phase (t(1/2) α), the half-life of elimination phase (t(1/2) β), volume of apparent distribution (Vd), and area under the concentration-time curve from zero to infinite time (AUC(0–t)) were 7.59 min, 46.99 min, 0.17 L/kg, and 204.5 mg/L/min, respectively, as determined by chromogenic substrate assay; 6.41 min, 47.28 min, 1.24 L/kg, and 575.18 mg/L/min, respectively, as determined by ELISA; 3.69 min, 701.90 min, 0.04 L/kg, and 4189 mg/L/min, respectively as determined by RA; and 4.57 min, 724.9 min, 0.09 L/kg, and 2329 mg/L/min, respectively, as determined by TCA-RA. CONCLUSIONS: The chromogenic substrate assay on the concentration dynamics of the recombinant hirudin in the plasma is a specific, sensitive, and accurate analytical method for pharmacokinetic studies. Moreover, the pharmacokinetic parameters determined by the chromogenic substrate assay and ELISA are congruent except for AUC. Public Library of Science 2013-06-13 /pmc/articles/PMC3681893/ /pubmed/23785400 http://dx.doi.org/10.1371/journal.pone.0064336 Text en © 2013 Jiang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jiang, Su-yun
Jiao, Jian
Zhang, Ting-ting
Xu, Yong-ping
Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays
title Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays
title_full Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays
title_fullStr Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays
title_full_unstemmed Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays
title_short Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays
title_sort pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, elisa, and radioisotope assays
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681893/
https://www.ncbi.nlm.nih.gov/pubmed/23785400
http://dx.doi.org/10.1371/journal.pone.0064336
work_keys_str_mv AT jiangsuyun pharmacokineticsstudyofrecombinanthirudinintheplasmaofratsusingchromogenicsubstrateelisaandradioisotopeassays
AT jiaojian pharmacokineticsstudyofrecombinanthirudinintheplasmaofratsusingchromogenicsubstrateelisaandradioisotopeassays
AT zhangtingting pharmacokineticsstudyofrecombinanthirudinintheplasmaofratsusingchromogenicsubstrateelisaandradioisotopeassays
AT xuyongping pharmacokineticsstudyofrecombinanthirudinintheplasmaofratsusingchromogenicsubstrateelisaandradioisotopeassays